This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Resumen de acción P0X
Pharnext SA, a clinical-stage biopharmaceutical company, engages in the development of therapies for neurodegenerative diseases with high unmet medical needs.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Competidores de Pharnext SA
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | €2.00 |
| 52 Week High | €80,000.00 |
| 52 Week Low | €0.35 |
| Beta | 313.03 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | -100.00% |
| 3 Year Change | -100.00% |
| 5 Year Change | n/a |
| Change since IPO | -100.00% |
Noticias y actualizaciones recientes
Recent updates
Rentabilidad de los accionistas
| P0X | DE Biotechs | Mercado DE | |
|---|---|---|---|
| 7D | n/a | -4.3% | -2.5% |
| 1Y | -100.0% | -19.4% | -0.4% |
Rentabilidad vs. Industria: P0X underperformed the German Biotechs industry which returned -6.2% over the past year.
Rentabilidad vs. Mercado: P0X underperformed the German Market which returned 12.1% over the past year.
Volatilidad de los precios
| P0X volatility | |
|---|---|
| P0X Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 9.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Precio estable de las acciones: P0X has not had significant price volatility in the past 3 months.
Volatilidad a lo largo del tiempo: Insufficient data to determine P0X's volatility change over the past year.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2007 | 23 | Hugo Brugiere | pharnext.com |
Resumen de fundamentos de Pharnext SA
| Estadísticas fundamentales de P0X | |
|---|---|
| Capitalización bursátil | €196.46k |
| Beneficios(TTM) | -€38.45m |
| Ingresos (TTM) | €2.26m |
0.1x
Ratio precio-ventas (PS)0.0x
Ratio precio-beneficio (PE)¿Está P0X sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de P0X | |
|---|---|
| Ingresos | €2.26m |
| Coste de los ingresos | €0 |
| Beneficio bruto | €2.26m |
| Otros gastos | €40.70m |
| Beneficios | -€38.45m |
Últimos beneficios comunicados
Dec 31, 2022
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -371.82 |
| Margen bruto | 100.00% |
| Margen de beneficio neto | -1,702.72% |
| Ratio deuda/patrimonio | -66.3% |
¿Cómo se ha desempeñado P0X a largo plazo?
Ver rendimiento histórico y comparativa